Reviva Pharma’s schizophrenia drug succeeds in late-stage study
Oct 30 (Reuters) – Reviva Pharmaceuticals Holdings (RVPH.O) said on Monday its lead experimental drug to treat adults with schizophrenia helped reduce disease symptoms in a late-stage study.
Schizophrenia is a chronic mental disorder that causes distortion in thoughts, hallucinations and feelings of fright and paranoia.
The drug, brilaroxazine, clocked a 10.1 point reduction, compared to a placebo, in a medical scale used to measure the severity of schizophrenia symptoms like delusions, hallucinations and emotional withdrawal among others.
Brilaroxazine belongs to a class of drugs called serotonin-dopamine signaling modulator which regulates the levels of two chemical messengers in the brain, serotonin and dopamine.
Reporting by Mariam Sunny in Bengaluru; Editing by Savio D’Souza